Vital Therapies completes merger with Immunic; shares up 33%

Seeking AlphaRead the rest

Vital Therapies (VTL) Announces Stockholder Approval of Business Combination with Immunic AG

Street InsiderRead the rest

Monteverde & Associates PC Announces an Investigation of Vital Therapies, Inc. – VTL

Cision PR NewswireRead the rest

Monteverde & Associates PC Announces an Investigation of Vital Therapies, Inc. – VTL

Cision PR NewswireRead the rest

Vital Therapies Appoints Russell J. Cox as Chief Executive Officer and Board Member Effective January 3, 2018

GlobenewswireRead the rest

Vital Therapies to Webcast Presentation at Upcoming Investor Conference

EconoTimesRead the rest

Vital Therapies Announces Second Quarter 2017 Financial Results

Globe NewswireRead the rest

Vital Therapies Announces Characteristics of Early Subjects in VTL-308 Pivotal Study of ELAD System in Severe Alcoholic Hepatitis

Globe NewswireRead the rest

Vital Therapies Announces First Quarter 2017 Financial Results

Globe NewswireRead the rest

Vital Therapies’ (VTL) CEO Terence Winters on Q4 2016 Results – Earnings Call Transcript

Seeking AlphaRead the rest

BRIEF-Vital Therapies Q4 loss per share $0.37

ReutersRead the rest

Vital Therapies Provides Corporate Update

click hereRead the rest

Vital Therapies Announces Appointment of Former Receptos President and CEO Faheem Hasnain to Its Board of Directors

click hereRead the rest